Although genomic alterations of ENO1 in BC are rare, an increased rate of ENO1 alterations in metastatic tumours as compared with primaries was identified, indicating that ENO1 alterations accumulate with progression and treatment. This evidence concerns the gene ENO1 and breast cancer.